This week, the Spanish Agency for Medicines and Health Products (AEMPS) approved the first clinical trials of PHH-1V, the Spanish vaccine against COVID-19, created by the pharmaceutical Hipra. According to the Minister of Science and Innovation, Diana Morant, in the program Window of the Cadena Ser, this vaccine could hit the market by the end of the year.
It is a vaccine developed from two proteins found in Alpha and Beta variants coronavirus, a different mechanism than Pfizer and Moderna messenger RNA. According explains the AEMPS, the combination of these two structurally similar compounds is “capable of generating a immune response against one of the proteins of the SARS-CoV-2 virus, known as protein S “ (from Spike), also called spike protein in Spanish. What is not clear yet is whether this serum will be able to be combined with those of other laboratories.
The pharmacist will test this vaccine in volunteers what will they receive two doses in a 21-day period. If the results are as expected, Hipra could start manufacturing it in October. It is possible that soon we will begin to hear the name of this pharmaceutical company next to that of Pfizer or Moderna. Therefore, it is convenient to know what advantages does it offer Hipra’s serum compared to those from other laboratories.
Easier to keep
Definitely, the strength of the PHH-1V vaccine will be its storage temperature. Messenger RNA vaccines should be stored ultra low temperatures Due to the instability of its molecules, which can be a logistical nightmare. In contrast, the Hipra can be stored between 2 and 8 degrees centigrade, which greatly facilitates its storage and distribution.
Protection against new variants
Another advantage of this Spanish vaccine is that, although it is based on proteins from the Alpha and Beta variants, it is able to protect against other variants such as the Delta, the most contagious. According to preliminary data from Hipra, his formula also generates a strong immune response against these strains.
Rhythm of production
The same in favor of the Spanish vaccine is the production capacity from the pharmaceutical company Hipra. If the deadlines are met, the company would manufacture a first batch of 75 million doses before 2022. The rate of production would increase to 400 million next year and would reach the 1.2 billion vaccines in 2023. This production far exceeds the demand in Spain, so that our country would become exporter of vaccines.
Vaccinate other countries
According to Minister Morant, the Spanish vaccine “has aroused quite a lot of interest in Europe”. With most of the world still to be vaccinated and with a large production capacity, Spain would be faced with the opportunity to become a global benchmark in the fight against COVID-19.